

RESEARCH ARTICLE

# An Extended Surface Loop on *Toxoplasma gondii* Apical Membrane Antigen 1 (AMA1) Governs Ligand Binding Selectivity

Michelle L. Parker, Martin J. Boulanger\*

Department of Biochemistry & Microbiology, University of Victoria, PO Box 3055 STN CSC, Victoria, BC, V8W 3P6, Canada

\* [mboulang@uvic.ca](mailto:mboulang@uvic.ca)



**OPEN ACCESS**

**Citation:** Parker ML, Boulanger MJ (2015) An Extended Surface Loop on *Toxoplasma gondii* Apical Membrane Antigen 1 (AMA1) Governs Ligand Binding Selectivity. PLoS ONE 10(5): e0126206. doi:10.1371/journal.pone.0126206

**Academic Editor:** Ira J Blader, University at Buffalo, UNITED STATES

**Received:** March 9, 2015

**Accepted:** March 31, 2015

**Published:** May 8, 2015

**Copyright:** © 2015 Parker, Boulanger. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All PDB files are available from the PDB database (accession numbers 4YIV, 4YIZ).

**Funding:** Funding provided by MOP82915, <http://www.cihr-irsc.gc.ca/e/193.html>. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

## Abstract

Apicomplexan parasites are the causative agents of globally prevalent diseases including malaria and toxoplasmosis. These obligate intracellular pathogens have evolved a sophisticated host cell invasion strategy that relies on a parasite-host cell junction anchored by interactions between apical membrane antigens (AMAs) on the parasite surface and rhoptry neck 2 (RON2) proteins discharged from the parasite and embedded in the host cell membrane. Key to formation of the AMA1-RON2 complex is displacement of an extended surface loop on AMA1 called the DII loop. While conformational flexibility of the DII loop is required to expose the mature RON2 binding groove, a definitive role of this substructure has not been elucidated. To establish a role of the DII loop in *Toxoplasma gondii* AMA1, we engineered a form of the protein where the mobile portion of the loop was replaced with a short Gly-Ser linker (*Tg*AMA1ΔDIIloop). Isothermal titration calorimetry measurements with a panel of RON2 peptides revealed an influential role for the DII loop in governing selectivity. Most notably, an *Eimeria tenella* RON2 (*Et*RON2) peptide that showed only weak binding to *Tg*AMA1 bound with high affinity to *Tg*AMA1ΔDIIloop. To define the molecular basis for the differential binding, we determined the crystal structure of *Tg*AMA1ΔDIIloop in complex with the *Et*RON2 peptide. When analyzed in the context of existing AMA1-RON2 structures, spatially distinct anchor points in the AMA1 groove were identified that, when engaged, appear to provide the necessary traction to outcompete the DII loop. Collectively, these data support a model where the AMA1 DII loop serves as a structural gatekeeper to selectively filter out ligands otherwise capable of binding with high affinity in the AMA1 apical groove. These data also highlight the importance of considering the functional implications of the DII loop in the ongoing development of therapeutic intervention strategies targeting the AMA1-RON2 invasion complex.

## Introduction

Parasites of phylum Apicomplexa cause devastating diseases on a global scale. Species within the *Plasmodium*, *Toxoplasma*, and *Eimeria* genera, for example, are the etiological agents of malaria, toxoplasmosis, and coccidiosis, respectively. *P. falciparum* causes the most severe cases of human malaria [1], while *T. gondii* infects up to a third of the world's human population and leads to a significant number of premature abortions in livestock [2], and *E. tenella* infections in chickens present an economic burden to the poultry industry estimated to exceed 1.5 billion dollars annually [3]. The widespread success of the apicomplexans relies on a conserved mechanism of host cell invasion, since access to the host cell interior is crucial for survival of these obligate intracellular parasites.

Apicomplexan parasites invade host cells using a highly orchestrated, step-wise mechanism. A parasite initially glides along cell surfaces, followed by reorientation and formation of a tight adhesion between the apical end of the parasite and the target host cell membrane. Subsequently, a circumferential ring of adhesion, termed the moving junction or tight junction, is formed through which the parasite propels itself while concurrently depressing the host cell membrane to form a nascent vacuole essential for parasite survival and replication [4, 5]. Supporting these invasion events are binary complexes formed between the apical membrane antigen (AMA) and rhoptry neck protein 2 (RON2) families that anchor the junction between parasite and host cell [6–10]. Specifically, RON2s are transmembrane proteins secreted by apicomplexans into the host cell, integrated into the outer membrane, and presented on the host cell surface to serve as ligands for AMA proteins on the parasite surface [7, 8, 11, 12]. The number of AMA and RON2 family members capable of forming functional invasion complexes vary across apicomplexans. For example, *Plasmodium spp.* harbour only a single copy of an AMA (AMA1) and RON2, while *T. gondii* and other *Eimeriorina*, such as *E. tenella*, have four AMAs (AMA1–4) and at least three RON2s (RON2, RON2<sub>L1</sub>, RON2<sub>L2</sub>) that show distinct and often stage-specific expression and interaction patterns [8, 13–16]. In *T. gondii*, AMA1 and AMA2 interact with RON2 in tachyzoites, AMA3-RON2<sub>L2</sub> functions in sporozoites, and the recently identified AMA4-RON2<sub>L1</sub> pairing is also predicted to play a role in sporozoites [7, 14, 15]. The expression of multiple AMA1 and RON2 paralogues within a species reflects the importance of this pairing to ensuring successful invasion.

Very limited cross-reactivity between AMA and RON2 proteins has been observed [17], yet the mechanisms that underlie this exquisite specificity are only partially understood. It is clear, however, that co-evolution between receptor and ligand plays a role in the selective AMA-RON2 binding events as illustrated by the structural and biochemical characterization of AMA proteins with the corresponding binding region of RON2 (RON2 domain 3; RON2D3) from *T. gondii* tachyzoites (AMA1-RON2D3) [18], *T. gondii* sporozoites (AMA3-RON2<sub>L2</sub>D3) [15], and *P. falciparum* merozoites (AMA1-RON2D3) [19]. The crystal structures of these AMA1-RON2 and AMA3-RON2<sub>L2</sub> complexes revealed that conformational changes in the apical surface of the AMA1/AMA3 protein are necessary to form a functional RON2 binding groove. In particular, a domain II loop (DII loop) of AMA1/AMA3 undergoes a substantial conformational change to reveal approximately half of the RON2 binding region. While several different roles have been proposed for the DII loop, including signalling associated with moving junction formation, regulating proteolytic processing of AMA1/AMA3, aiding in host immune evasion, and selectively filtering potential binding partners, a definitive role has yet to be elucidated [15, 18, 20–22]. Moreover, the differing length, composition, and flexibility of the DII loop across apicomplexan AMAs leads to highly divergent conformations that suggest the potential for genus-specific functions [17, 23–27].

To investigate the role of the *T. gondii* AMA1 DII loop, we engineered a construct of *TgAMA1* lacking the flexible portion of the DII loop (*TgAMA1* $\Delta$ DIIloop) and compared it with *TgAMA1* for the ability to coordinate a diverse panel of RON2 peptides. Intriguingly, DII loop dependent differences in RON2 coordination were observed. Most notably, an *E. tenella* RON2 peptide (*EtRON2D3*) showed significantly tighter binding to *TgAMA1* $\Delta$ DIIloop relative to *TgAMA1*. Subsequent structural characterization of *TgAMA1* $\Delta$ DIIloop in complex with *EtRON2D3* provides the first high-resolution view of a cross-genus AMA1-RON2 complex and yields important insight into the AMA1-RON2 coordination event. Collectively, these data reveal a gatekeeper role for the DII loop as it selectively filters access to the AMA1 groove, ensuring exquisite specificity and regulating assembly of the AMA1-RON2 invasion complex.

## Materials and Methods

### Cloning, protein production and purification

A sequence encoding the mature ectoplasmic region of *TgAMA1* (amino acids 64 to 484, TGME49\_255260 [24]) with the twenty residues of the DII loop disordered in the *TgAMA1*-*TgRON2D3* co-structure [18] replaced by a seven residue Gly-Ser linker (*TgAMA1* $\Delta$ DIIloop) was synthesized and subcloned into a modified pAcGP67b vector (Pharmlingen) with a C-terminal thrombin cleavage site and hexahistidine tag. *TgAMA1* $\Delta$ DIIloop encoding virus for insect cell protein production was generated and amplified using established protocols [18, 24]. Following a 65 hr infection the supernatant was harvested, concentrated, and *TgAMA1* $\Delta$ DIIloop was purified by nickel batch binding as previously described [17]. The hexahistidine tag was removed by thrombin cleavage and the protein was further purified by size exclusion chromatography (SEC) (Superdex 16/60 75) in HEPES buffered saline (HBS; 20 mM HEPES pH 7.5, 150 mM NaCl).

A sequence encoding a portion of *EtRON2D3* (amino acids 1262 to 1297, ETH\_00012760) was synthesized and subcloned into a modified pET32a vector (Novagen) incorporating N-terminal hexahistidine and thioredoxin (TRX) tags with a thrombin cleavage site. The fusion protein was produced in *E. coli* BL21 cells. For crystallization, *EtRON2D3*-TRX was cleaved to remove the fusion tags and co-purified with *TgAMA1* $\Delta$ DIIloop by SEC in HBS followed by anion exchange chromatography using a Source 30Q column (20 mM HEPES pH 8.0, 10 mM NaCl; elution gradient with 20 mM HEPES pH 8.0, 1 M NaCl) to remove residual TRX tag.

For ITC experiments, *TgAMA1* was produced and purified as previously reported [24]. Thioredoxin fusions of *TgRON2D3*, *TgRON2<sub>L1</sub>D3*, *TgRON2<sub>L2</sub>D3*, *EtRON2D3* and *PfRON2D3* were produced in *E. coli* BL21 cells and purified by nickel-affinity and SEC.

### Isothermal Titration Calorimetry

Purified *TgAMA1*, *TgAMA1* $\Delta$ DIIloop, and TRX fusions of *TgRON2D3*, *TgRON2<sub>L1</sub>D3*, *TgRON2<sub>L2</sub>D3*, *EtRON2D3*, and *PfRON2D3* were dialyzed against HBS at 4 °C. All ITC experiments were carried out at 25 °C on a MicroCal iTC200 instrument (GE Healthcare). The sample cell contained *TgAMA1* or *TgAMA1* $\Delta$ DIIloop (10 to 16  $\mu$ M for nanomolar affinity, 35 to 75  $\mu$ M for micromolar affinity), and the TRX-fused peptides (110 to 180  $\mu$ M for nanomolar affinity, 360 to 1180  $\mu$ M for micromolar affinity) were added in 17 injections of 2  $\mu$ L each. TRX was injected as a negative control and showed no detectable binding. Data were processed using Origin software (MicroCal) and the dissociation constants ( $K_d$ ) were determined using a one-site model. Values are derived from a single experiment, but are representative of at least two independent experiments.

## Native gel electrophoresis assay

Purified *TgAMA1* $\Delta$ DIIloop and co-purified *TgAMA1* $\Delta$ DIIloop-*EtRON2D3* protein samples in HBS were run on an 8–25% gradient native gel using the PhastGel system (GE Healthcare), and protein bands were visualized with Coomassie Brilliant Blue staining.

## Crystallization and data collection

Using a Crystal Gryphon (Art Robbins Instruments), crystals of *TgAMA1* $\Delta$ DIIloop were grown in 5 mM cobalt (II) chloride hexahydrate, 5 mM nickel (II) chloride hexahydrate, 5 mM cadmium chloride hydrate, 5 mM magnesium chloride hexahydrate, 0.1 M HEPES pH 7.5, 12% PEG 3350, and 2% glycerol. The final drops for *TgAMA1* $\Delta$ DIIloop consisted of 0.3  $\mu$ L protein (14 mg/mL) with 0.6  $\mu$ L reservoir solution and were equilibrated against 55  $\mu$ L of reservoir solution. Cryoprotection of the *TgAMA1* $\Delta$ DIIloop crystals was carried out in reservoir solution supplemented with 25% glycerol for 20 seconds and the crystals were flash cooled at 100 K directly in the cryo stream.

Using the sitting drop method, crystals of *TgAMA1* $\Delta$ DIIloop-*EtRON2D3* were grown in 0.1 M tri-sodium citrate pH 5.0 and 2.0 M ammonium sulfate. The final drops for *TgAMA1* $\Delta$ DIIloop-*EtRON2D3* consisted of 1.2  $\mu$ L protein (15 mg/mL) with 1.8  $\mu$ L reservoir solution and were equilibrated against 100  $\mu$ L of reservoir solution. Cryoprotection of the *TgAMA1* $\Delta$ DIIloop-*EtRON2D3* crystals was carried out in a 3:1 ratio of 2.5 M lithium sulfate: 1.0 M sodium sulfate for 20 seconds and the crystals were flash cooled at 100 K directly in the cryo stream. All diffraction data were collected on beamline 12–2 at the Stanford Synchrotron Radiation Lightsource (SSRL).

## Data processing, structure solution and refinement

Diffraction data were processed using Imosflm [28] and Scala [29] in the CCP4 suite of programs [30]. Initial phases for both *TgAMA1* $\Delta$ DIIloop and *TgAMA1* $\Delta$ DIIloop-*EtRON2D3* were obtained by molecular replacement using PHASER [31] with *TgAMA1* DI-DII-DIII from the complex with *TgRON2D3* (PDB ID: 2Y8T). Solvent molecules were selected using COOT [32] and refinement carried out using Phenix.refine [33]. Structural validation was performed with Molprobity [34]. Overall, 5% of the reflections were set aside for calculation of  $R_{\text{free}}$ . Data collection and refinement statistics are presented in Table 1. The atomic coordinates and structure factors have been deposited in the Protein Data Bank: *TgAMA1* $\Delta$ DIIloop (PDB ID: 4YIV); *TgAMA1* $\Delta$ DIIloop-*EtRON2D3* (PDB ID: 4YIZ).

## Results

### Engineered deletion of the *TgAMA1* DII loop reveals a mature apical ligand binding groove

*Toxoplasma gondii* AMA1 adopts a stacked three domain architecture, with Domain I (DI) membrane distal and Domain III (DIII) membrane proximal [24]. The apical surface is comprised of several loops from DI framing an apical groove, and a single extended loop from DII (DII loop) that packs against the side of DI and is stabilized by three tryptophan anchors buried into pockets on the *TgAMA1* apical surface (Fig 1A and 1B). Previous structural characterization of *TgAMA1* in complex with a RON2 peptide (*TgRON2D3*) revealed that in order for RON2 to access the *TgAMA1* apical groove, the groove-occluding DII loop must be displaced (Fig 1C) [18]. To probe the role of the DII loop, we engineered a construct of *TgAMA1* with the twenty residue mobile portion of the DII loop replaced with a shortened Gly-Ser linker (*TgAMA1* $\Delta$ DIIloop). This engineered construct of *TgAMA1* was produced in insect cells,

**Table 1. Data collection and refinement statistics.**

	<i>Tg</i> AMA1ΔDIIIloop	<i>Tg</i> AMA1ΔDIIIloop-EtRON2D3
<b>A. Data collection statistics</b>		
Spacegroup	P4 <sub>1/3</sub> 2 <sub>1</sub> 2	P3 <sub>1/2</sub> 2
a, b, c (Å)	89.05, 89.05, 124.97	265.93, 265.93, 94.16
α, β, γ (deg.)	90, 90, 90	90, 90, 120
Wavelength	0.9795	0.9795
Resolution range (Å)	56.24–1.93 (2.11–1.93)	72.89–2.20 (2.32–2.20)
Measured reflections	297853 (43802)	782702 (112655)
Unique reflections	38493 (5516)	180412 (26362)
Redundancy	7.7 (7.9)	4.3 (4.3)
Completeness (%)	99.8 (91.9)	93.9 (94.4)
<i>I</i> / $\sigma$ ( <i>I</i> )	13.8 (4.0)	6.6 (3.4)
R <sub>merge</sub> <sup>a</sup>	0.081 (0.494)	0.133 (0.475)
<b>B. Refinement statistics</b>		
Spacegroup	P4 <sub>1</sub> 2 <sub>1</sub> 2	P3 <sub>2</sub> 2
Resolution (Å)	51.15–1.93	59.50–2.20
R <sub>work</sub> <sup>b</sup> /R <sub>free</sub> <sup>c</sup>	0.176/0.195	0.187/0.207
No. of atoms		
Protein (A/B/C/D/E/F)	2950	3119/271/3099/271/3061/271
Sulfate	N/A	25
Co/Cd/Cl	3/2/2	N/A
Glycerol	12	N/A
Solvent	234	487
B-values (Å <sup>2</sup> )		
Protein (A/B/C/D/E/F)	36.2	30.7/43.9/36.9/38.9/35.6/40.0
Sulfate	N/A	68.0
Co/Cd/Cl	44.9/28.7/27.8	N/A
Glycerol	45.1	N/A
Solvent	38.8	33.3
r.m.s. deviation from ideality		
Bond lengths (Å)	0.013	0.004
Bond angles (deg.)	1.39	1.12
Ramachandran statistics (%)		
Most favoured	98.1	98.0
Allowed	1.9	2.0
Disallowed	0.0	0.0

Values in parentheses are for the highest resolution shell


<sup>a</sup> R<sub>merge</sub> =  $\sum_{hkl} \sum_i |I_{hkl,i} - [I_{hkl}]| / \sum_{hkl} \sum_i I_{hkl,i}$ , where  $[I_{hkl}]$  is the average of symmetry related observations of a unique reflection

<sup>b</sup> R<sub>work</sub> =  $\sum |F_{obs} - F_{calc}| / \sum F_{obs}$ , where F<sub>obs</sub> and F<sub>calc</sub> are the observed and the calculated structure factors, respectively

<sup>c</sup> R<sub>free</sub> is R using 5% of reflections randomly chosen and omitted from refinement

doi:10.1371/journal.pone.0126206.t001

purified, crystallized, and the apo crystal structure solved to 1.93 Å resolution. Superposition of *Tg*AMA1ΔDIIIloop on RON2-bound *Tg*AMA1 resulted in a root mean square deviation (rmsd) of 0.70 Å over 365 Cα, indicating strong structural conservation of the protein core. Importantly, a comparison of the apical loops that frame the length of the ligand binding groove showed a maximum deviation of 0.91 Å with an average rmsd of 0.35 Å over 13 to 21 Cαs for the six DI loops indicating that minimal displacement of these loops in *Tg*AMA1ΔDIIIloop is necessary




**Fig 1. Engineered form of *TgAMA1* with a truncated DII loop presents a mature ligand binding groove.** (A) Side view of apo *TgAMA1* (PDB ID: 2X2Z) displayed as a grey surface. Residues of *TgAMA1* DI and DII that interact with the DII loop are colored purple. The DII loop is shown as an orange cartoon, with residues that are displaced upon RON2 binding shown as ball-and-stick and colored by element. The arrow indicates the RON2 ligand binding groove. (B) Apical view of *TgAMA1*, colored as in (A). The three Trp residues at the tip of the DII loop that anchor it into the apical surface are shown as sticks: W350, W353, W354. (C) Apical view of *TgAMA1* (colored as in (A)) complexed with *TgRON2* (green cartoon backbone, with disulfide bond shown in ball-and-stick) from PDB ID 2Y8T. The displaced region of the *TgAMA1* DII loop is indicated by a dotted orange line. (D) Apical (left) and side (right) view of *TgAMA1*ΔDIIloop shown as a grey surface, with residues that correspond to DII loop coordinating residues of apo *TgAMA1* colored purple, and the truncated DII loop colored orange; the disordered Gly-Ser linker is shown as an orange dotted line. The arrow indicates the mature ligand binding groove presented in the absence of the DII loop.

doi:10.1371/journal.pone.0126206.g001

for ligand coordination. Overall, truncation of the DII loop in *TgAMA1*ΔDIIloop appears to faithfully mimic the displaced DII loop form of *TgAMA1* (Fig 1C) and thereby present a mature ligand binding groove (Fig 1D).

### *TgAMA1* is a more promiscuous receptor in the absence of the DII loop

To determine how the absence of the DII loop affected AMA1-RON2 complex formation, we used ITC to measure the solution binding characteristics of several RON2D3 peptides to *TgAMA1* or *TgAMA1*ΔDIIloop (Fig 2A and 2B). *TgAMA1* bound to *TgRON2D3* with a low nanomolar affinity (5.8 nM or greater), consistent with previously published SPR measurements [18]. *TgAMA1* showed weak binding to *EtRON2D3* (2.2 μM), while binding was not detectable (ND—estimated to be in millimolar range and therefore likely not relevant to anchoring the junction) for *Toxoplasma* RON2 paralogues (*TgRON2<sub>L1</sub>D3* and *TgRON2<sub>L2</sub>D3*) or *PfRON2D3*, consistent with previously established selectivity of *TgAMA1* for *TgRON2D3* [14, 15, 18]. Intriguingly, *TgAMA1*ΔDIIloop displayed notably different binding profiles compared to *TgAMA1*, aside from a similar affinity for the cognate ligand, *TgRON2D3* (Fig 2B). Most strikingly, *EtRON2D3* bound approximately 275 fold tighter to *TgAMA1*ΔDIIloop (8.0



ND, interaction not detected

**Fig 2. Isothermal titration calorimetry shows that the DII loop limits the reactivity of TgAMA1.** (A) Representative ITC thermograms for low affinity (left: *Et*RON2D3-TRX titrated into *Tg*AMA1) and high affinity (right: *Et*RON2D3-TRX titrated into *Tg*AMA1ΔDIIloop) complex formation. (B) Table of ITC results comparing binding affinity and thermodynamic parameters for *Tg*AMA1 and *Tg*AMA1ΔDIIloop binding to a panel of TRX-fused RON2D3 peptides at 25 °C.

doi:10.1371/journal.pone.0126206.g002

nM or greater) relative to *Tg*AMA1 (2.2 μM). In addition, binding was detected between *Tg*AMA1ΔDIIloop and *Tg*RON2<sub>L2</sub>D3, *Tg*RON2<sub>L1</sub>D3 and *Pf*RON2D3 in the micromolar range (6.0, 46, and 1.4 μM, respectively) (Fig 2B). Despite the comparatively weaker affinities, each of these three interactions was saturable and showed a stoichiometry close to 1:1 consistent with genuine complex formation. Collectively, these results suggest that while the *Tg*AMA1 groove is fundamentally capable of interacting with all the RON2D3 peptides tested, the presence of the DII loop imparts remarkable selectivity.

## Structural basis of *TgAMA1*ΔDIIloop-*EtRON2D3* complex formation




The significant differential binding observed between *EtRON2D3* and *TgAMA1* or *TgAMA1*ΔDIIloop provided an experimentally tractable starting point from which to investigate the structural basis of how the DII loop governs selectivity. While *TgAMA1*ΔDIIloop in the presence or absence of *EtRON2D3* eluted in the same volume off the SEC column (Fig 3A), native PAGE analysis clearly showed an altered migration for the sample co-purified with *EtRON2D3* (pI of 3.9) indicating that the peptide was retained by *TgAMA1*ΔDIIloop throughout the purification process (Fig 3A, inset). The 2.20 Å resolution crystal structure of *TgAMA1*ΔDIIloop in complex with *EtRON2D3* showed clear electron density for the peptide seated in the apical groove (Fig 3B). Three complexes in the asymmetric unit showed little variation in overall structure (*TgAMA1*ΔDIIloop: 0.32/0.60 Å rmsd over 392/387 C $\alpha$ , chain A compared to C/E; *EtRON2D3*: 0.23/0.32 Å rmsd over 39/39 C $\alpha$ , chain B compared to D/F), although an O-linked glycosylation on Thr425 of the DII-DIII linker was modelled only in chain A. Since *EtRON2D3* chain D showed the lowest thermal motion (Table 1), the *TgAMA1*ΔDIIloop chain C complex with *EtRON2D3* chain D was used for further analyses unless otherwise noted.

*EtRON2D3* bound throughout the apical groove of *TgAMA1*ΔDIIloop in the expected conformation based on previous AMA1-RON2 co-structures [15, 18, 19], with the *EtRON2D3* N-terminal helix seated in the area exposed by the absence of the *TgAMA1* DII loop, followed by a length of ordered coil, a beta-hairpin loop, and ordered C-terminal coil that extends back through the apical groove (Fig 3B). In contrast to previously characterized AMA1-RON2 complexes, the electron density surrounding the cysteine residues of *EtRON2D3* (Cys1278 and Cys1288) revealed a population with only a partially formed disulfide bond. While the second cysteine (Cys1288) was appropriately positioned to form the disulfide, density based refinement of the occupancy for the first cysteine (Cys1278) showed 41 to 74% oriented away from the central axis of the disulfide bond (Fig 3B, inset). While the basis for this observation is unclear, it is possible that the less than ideal fit of *EtRON2D3* into the *TgAMA1* groove may contribute to this anomaly.

## RON2 must engage both ends of the AMA1 groove to outcompete the DII loop

An initial comparison of the *TgAMA1*-*TgRON2D3* and *TgAMA1*ΔDIIloop-*EtRON2D3* interfaces revealed similar overall buried surface areas (~3400 Å<sup>2</sup> for each complex [35]), but an overlay of the *TgRON2D3* peptide on the *TgAMA1*ΔDIIloop-*EtRON2D3* complex shows key areas of divergence. Most importantly, the N-terminal helix adopts a different angle between the two peptides, the coil leading up to the first cysteine is restructured, and the tip of the cysteine loop is shifted (Fig 3C). To investigate how these differences contribute to the inability of *EtRON2D3* to outcompete the DII loop of *TgAMA1*, we first examined the stabilizing hydrogen bond network between *TgRON2D3* or *EtRON2D3* and the *TgAMA1* apical groove. Overall, the *TgAMA1*ΔDIIloop-*EtRON2D3* complex retains only sixteen of the twenty hydrogen bonds observed in the *TgAMA1*-*TgRON2D3* complex [18], consistent with the less favorable enthalpy measured for *TgAMA1*ΔDIIloop-*EtRON2D3* by ITC (Fig 2B). Notably, the four hydrogen bonds that *EtRON2D3* fails to form map to the N- and C-terminal regions of *TgRON2D3* that overlap with the hydrogen bond network of the DII loop in apo *TgAMA1* (Table 2) [35]. Specifically, the eight hydrogen bonds that must be broken to displace the DII loop from the apical groove are compensated for by the ten hydrogen bonds formed between *TgAMA1* and *TgRON2D3* in the overlapping region, contrasted against only six between *TgAMA1*ΔDIIloop and *EtRON2D3*. We next assessed the number of interatomic contacts less than 3.9 Å formed between *TgAMA1* and each residue of the DII loop, *TgRON2D3*, or *EtRON2D3*.





**Fig 3. Characterization of a cross-genus AMA1-RON2 complex: *Tg*AMA1ΔDIIloop-*Et*RON2D3. (A)** Size exclusion chromatograms of *Tg*AMA1ΔDIIloop with and without *Et*RON2D3 showing elution at the same volume. Globular molecular weight standards: I—75 kDa, II—43 kDa, III—29 kDa. Inset—gradient native PAGE of *Tg*AMA1ΔDIIloop without and with *Et*RON2D3 showing an effect on the migration of *Tg*AMA1ΔDIIloop in the presence of *Et*RON2D3. **(B)** Top—Apical view of *Tg*AMA1ΔDIIloop (grey surface) bound to *Et*RON2D3 (cyan cartoon backbone, disulfide and partially free cysteine shown as ball-and-stick and highlighted with black dotted oval). Bottom—Sigma-A weighted 2Fo-Fc electron density map contoured at 1.0 σ for *Et*RON2D3. Inset—zoom in on the electron density of the two Cys of *Et*RON2D3 chain F, which had the closest to 50% occupancy in each position for Cys1278. **(C)** Superposition of *Tg*RON2D3 on the *Tg*AMA1ΔDIIloop-*Et*RON2D3 complex. Different angles of the N-terminal helices are indicated by the dotted black oval; altered positioning of the *Et*RON2D3 coil leading up to the partially formed disulfide, white arrow; divergence of the cysteine loop tip, black arrow.

doi:10.1371/journal.pone.0126206.g003


The analysis of the DII loop revealed six key interaction points that must be disrupted in order to accommodate a ligand: Tyr342 forms a clamp near the base of the DII loop while Trp350, Trp353, Trp354, Pro355, and His357 all anchor the tip of the DII loop into the *Tg*AMA1 apical groove (Fig 4A). *Tg*RON2D3, which is capable of binding *Tg*AMA1 in the presence or absence of the DII loop, forms critical anchor points throughout the groove and in particular at the base of the N-terminal helix, the Pro residue between the helix and disulfide bond, and the five residues that form the tip of the cystine loop (Fig 4B). Importantly, these three regions correspond to the regions of altered topology between the two peptides (Fig 3C), and also correlate to regions with the largest number of contacts lost by *Et*RON2D3. In particular, three residues at the base of the N-terminal helix of *Tg*RON2D3 form extensive contacts to the *Tg*AMA1 groove, while the analogous residues of *Et*RON2D3 are positioned similarly but make one third the number of contacts (Fig 4C). The differences around the proline and the first cysteine

**Table 2. Comparison of hydrogen bonds (< 3.5 Å or conserved) observed at the *Tg*AMA1ΔDIIloop-*Et*RON2D3 and *Tg*AMA1-*Tg*RON2D3 interfaces.**

<i>Et</i> RON2D3	<i>Tg</i> AMA1 ΔDII loop	Distance (Å)	<i>Tg</i> RON2D3	<i>Tg</i> AMA1	Distance (Å)
			Glu1303 [Oε2]	Arg111 [N]	3.46
			Glu1303 [Oε1]	Gln361 [Nε2]	2.55
Asp1269 [Oδ1]	Gln361 [Nε2]	2.83	Asp1304 [Oδ1]	Gln361 [Nε2]	2.75
Asp1269 [O]	Arg111 [NH1]	2.87	Asp1304 [O]	Arg111 [NH1]	2.98
<b>Gly1271 [O]</b>	<b>Met233 [N]</b>	<b>3.74</b>	<b>Gly1306 [O]</b>	<b>Met233 [N]</b>	<b>3.65</b>
Val1276 [N]	Tyr230 [OH]	3.57	Val1311 [N]	Tyr230 [OH]	3.54
Val1276 [O]	Tyr230 [OH]	3.42	Val1311 [O]	Tyr230 [OH]	2.56
<b>Cys1278 [O]</b>	<b>Met204 [N]</b>	<b>3.04</b>	<b>Cys1313 [O]</b>	<b>Met204 [N]</b>	<b>3.06</b>
<b>Glu1280 [N]</b>	<b>Val202 [O]</b>	<b>2.96</b>	<b>Thr1315 [N]</b>	<b>Val202 [O]</b>	<b>2.90</b>
<b>Glu1280 [O]</b>	<b>Val202 [N]</b>	<b>3.06</b>	<b>Thr1315 [O]</b>	<b>Val202 [N]</b>	<b>2.85</b>
Asn1281 [Nδ2]	Phe197 [O]	3.58	Asn1316 [Nδ2]	Phe197 [O]	3.47
Asn1281 [Nδ2]	Lys200 [O]	3.58	Asn1316 [Nδ2]	Lys200 [O]	3.70
Asn1281 [Nδ2]	Thr201 [Oγ1]	2.63	Asn1316 [Nδ2]	Thr201 [Oγ1]	2.76
<b>Leu1282 [N]</b>	<b>Lys200 [O]</b>	<b>3.27</b>	<b>Glu1317 [N]</b>	<b>Lys200 [O]</b>	<b>2.99</b>
<b>Cys1288 [N]</b>	<b>Val164 [O]</b>	<b>3.04</b>	<b>Cys1323 [N]</b>	<b>Val164 [O]</b>	<b>2.92</b>
<b>Cys1288 [O]</b>	<b>Val164 [N]</b>	<b>2.77</b>	<b>Cys1323 [O]</b>	<b>Val164 [N]</b>	<b>2.94</b>
<b>Val1292 [O]</b>	<b>Glu145 [N]</b>	<b>2.85</b>	<b>Ala1327 [O]</b>	<b>Glu145 [N]</b>	<b>2.87</b>
<b>Ala1294 [N]</b>	<b>Pro143 [O]</b>	<b>3.12</b>	<b>Ala1329 [N]</b>	<b>Pro143 [O]</b>	<b>2.97</b>
			Lys1330 [N]	Glu145 [Oε1]	3.16
			Ala1331 [O]	Trp253 [Nε1]	3.35

Sidechain independent interactions are bolded.

doi:10.1371/journal.pone.0126206.t002



**Fig 4. Interatomic contacts between *TgAMA1* and RON2D3 reveal high contact density areas likely required to outcompete the DII loop.** (A) Heat map coloring scheme based on number of interatomic contacts from white (no contacts) to red (>10 contacts) shows that the DII loop (cartoon backbone with ball-and-stick sidechains) is anchored into the *TgAMA1* apical surface predominately through six residues, five of which are located in the apical groove (PDB ID: 2X2Z). (B) A similar analysis of contacts at the *TgAMA1-TgRON2D3* interface (PDB ID: 2Y8T) shows that anchoring of the RON2 peptide occurs at the base of the N-terminal helix (black arrowhead), a proline in between the helix and disulfide bond, and the tip of the cystine loop (black arrow). (C) A contact heat map of the *TgAMA1ΔDIIloop-EtRON2D3* interface shows major reductions in the number of contacts formed between the *TgAMA1* apical groove and both the base of the RON2 helix (black arrowhead) and the tip of the cystine loop (black arrow). (D) Disulfide-anchored (black bar) sequence alignment of RON2D3 peptides used in this study, with the secondary structure representative of all peptides except the uncharacterized *TgRON2<sub>L1</sub>D3* (light grey) shown above, and *TgRON2D3/EtRON2D3* sequences colored on the interatomic contact heat map scale. Underlined residues correspond to anchored regions with highest interatomic contact density.

doi:10.1371/journal.pone.0126206.g004

are likely related to incomplete closure of the *EtRON2D3* disulfide bond, and the Val-Val pair at the tip of the cystine loop is the only other region where consecutive residues of *EtRON2D3* make substantially fewer interatomic contacts with *TgAMA1* compared to *TgRON2D3* (Fig 4D). Together, these analyses suggest that in order to maintain the DII loop in a displaced conformation, the ligand must engage anchor points in both the region exposed by displacement of the DII loop and at the opposite end of the AMA1 apical groove.

## Discussion

High affinity AMA-RON2 complexes anchor the junction between apicomplexan parasites and host cells and play an important role in invasion [10, 14, 36]. Functional and biophysical dissection of cognate AMA-RON2 pairs has led to detailed insight into how these complexes support invasion, which has in turn helped guide the development of novel therapeutic intervention strategies [15, 18, 19, 37, 38]. Notably, the AMA1-RON2 complex was recently shown to be significantly more immuno-protective than AMA1 alone for malaria [39, 40], and the development of pharmacophore models describing the AMA1 ligand binding groove have led to *in silico* docking experiments and corresponding proof of principle invasion inhibition studies [17, 41–44]. To further probe the complexities of this sophisticated invasion complex, we have interrogated the role of the AMA1 DII loop, a key substructure that must be displaced for RON2 binding [15, 18, 19, 23, 24].

Initially, we engineered a form of *T. gondii* AMA1 where the flexible region of the DII loop was replaced with a short Gly-Ser linker (Fig 1). Solution binding analyses using a diverse panel of RON2 peptides revealed a critical role for the DII loop in regulating *Tg*AMA1 selectivity. Notably, *Tg*AMA1 bound both *Tg*RON2D3 and *Et*RON2D3 but only the former with high affinity, while *Tg*AMA1 $\Delta$ DIIloop showed moderate binding to each tested RON2D3 and bound both *Tg*RON2D3 and *Et*RON2D3 with high affinity (Fig 2). To establish the molecular basis for the observed differential binding, we determined the structure of *Tg*AMA1 $\Delta$ DIIloop in complex with *Et*RON2D3. Notably, this is the first cross-genus AMA-RON2 pair to be structurally characterized (Fig 3). A comparison of contacts in the *Tg*AMA1-*Tg*RON2D3 and *Tg*AMA1 $\Delta$ DIIloop-*Et*RON2D3 structures enabled the identification of key anchor points in the AMA1 groove exploited to outcompete the DII loop and bind *Tg*AMA1 with high affinity (Fig 4). Intriguingly, the anchor points identified at the base of the RON2 N-terminal helix and the tip of the cystine loop correlate with the regions in which the most successful linear peptide inhibitor of the AMA1-RON2 interaction to date, peptide R1, binds *Pf*AMA1 [19, 45]. These data further support a role for the DII loop in tuning AMA1 selectivity. The detailed mechanism by which the DII loop achieves the required selectivity, however, remains to be determined and will likely require measuring pre-equilibrium kinetics of association and dissociation between RON2 and both native and  $\Delta$ DIIloop forms of AMA1 from *T. gondii* and *P. falciparum*.

The biological implications of truncating the DII loop have proven difficult to assess. However, since the presence of the AMA1 DII loop results in a more selective receptor, this substructure may act as a structural gatekeeper to restrict formation of unproductive AMA1 complexes. Thus, a more discriminating AMA1 apical groove would ensure the parasite-host cell junction is competent for invasion because only a cognate RON2 would bind with sufficient affinity to outcompete the DII loop. This gatekeeping function may ultimately serve as a molecular switch to signal the parasite that a functional junction has been formed and invasion can proceed. It follows that an apicomplexan parasite expressing the truncated DII loop form of AMA1 might experience more abortive invasion events resulting from unproductive, non-RON2 based AMA1 complexes that are not linked to junction integrity. The potential for AMA1 to form non-RON2 based complexes has been proposed [46–50], particularly in *Plasmodium*, and it is even suggested that a complex between AMA1 and a host surface protein may support a pre-invasion step [51]. In this case the parasite would use AMA1 as a simple adhesin without activating the motor system to drive invasion. While no host cell ligands have been identified that bind the apical groove of AMA1, weak affinities that rely on receptor clustering in a cellular context may have limited their identification. Using AMA1  $\Delta$ DIIloop truncation constructs in pulldown assays with host lysates may overcome this limitation as we have shown in the case of *Tg*AMA1 that the  $\Delta$ DIIloop construct displays a more permissive binding profile. Furthermore, engineering parasites to express  $\Delta$ DIIloop constructs of AMA1 will enable the investigation of potential DII loop dependant signalling events associated with high affinity AMA1-RON2 binary complex assembly and moving junction formation.

## Conclusions

The solution binding studies of several RON2 peptides with *Tg*AMA1 and *Tg*AMA1 $\Delta$ DIIloop reveal a previously underappreciated role for the DII loop in selectively filtering out ligands otherwise capable of binding in the AMA1 apical groove. Companion structural studies offer important insight into molecular recognition thresholds that likely need to be achieved by ligands able to outcompete the DII loop and form high affinity complexes capable of anchoring the moving junction during invasion of the host cell. While the biological implications of

apicomplexan AMA1 DII loop conformational changes remain an intriguing topic for future studies, these results provide a molecular basis for understanding AMA1 selectivity, which can support the development of novel therapies targeting the important AMA1-RON2 invasion complexes.

## Acknowledgments

The authors gratefully acknowledge the staff at the Stanford Synchrotron Radiation Light-source (SSRL). MJB is a Michael Smith Foundation for Health Research (MSFHR) scholar and a Canada Research Chair.

## Author Contributions

Conceived and designed the experiments: MLP MJB. Performed the experiments: MLP. Analyzed the data: MLP MJB. Contributed reagents/materials/analysis tools: MLP MJB. Wrote the paper: MLP MJB.

## References

1. World Health Organization. World malaria report. Geneva, Switzerland: World Health Organization; 2010.
2. Tenter AM, Heckeroth AR, Weiss LM. *Toxoplasma gondii*: from animals to humans. *Int J Parasitol*. 2000; 30(12–13): 1217–1258. PMID: [11113252](#).
3. Ruff MD. Important parasites in poultry production systems. *Vet Parasitol*. 1999; 84(3–4): 337–347. doi: [10.1016/S0304-4017\(99\)00076-X](#) PMID: [10456422](#).
4. Carruthers V, Boothroyd JC. Pulling together: an integrated model of *Toxoplasma* cell invasion. *Curr Opin Microbiol*. 2007; 10(1): 83–89. doi: [10.1016/j.mib.2006.06.017](#) PMID: [16837236](#).
5. Aikawa M, Miller LH, Johnson J, Rabbege J. Erythrocyte entry by malarial parasites. A moving junction between erythrocyte and parasite. *J Cell Biol*. 1978; 77(1): 72–82. PMID: [96121](#).
6. Lamarque M, Besteiro S, Papoin J, Boulanger MJ, Tomavo S, Lebrun M. The RON2-AMA1 interaction is a critical step in the moving-junction-dependent invasion by Apicomplexa parasites. *PLoS Pathog*. 2011; 7(2): e1001276. doi: [10.1371/journal.ppat.1001276](#) PMID: [21347343](#)
7. Tyler JS, Boothroyd JC. The C-terminus of *Toxoplasma* RON2 provides the crucial link between AMA1 and the host-associated invasion complex. *PLoS Pathog*. 2011; 7(2): e1001282. doi: [10.1371/journal.ppat.1001282](#) PMID: [WOS:000287698200020](#).
8. Srinivasan P, Beatty WL, Diouf A, Herrera R, Ambroggio X, Moch JK, et al. Binding of Plasmodium merozoite proteins RON2 and AMA1 triggers commitment to invasion. *Proc Natl Acad Sci U S A*. 2011; 108(32): 13275–13280. doi: [10.1073/pnas.1110303108](#) PMID: [21788485](#).
9. Harvey KL, Yap A, Gilson PR, Cowman AF, Crabb BS. Insights and controversies into the role of the key apicomplexan invasion ligand, Apical Membrane Antigen 1. *Int J Parasitol*. 2014; 44(12): 853–857. doi: [10.1016/j.ijpara.2014.08.001](#) PMID: [25157917](#).
10. Weiss GE, Gilson PR, Taechalerpaisarn T, Tham WH, de Jong NW, Harvey KL, et al. Revealing the Sequence and Resulting Cellular Morphology of Receptor-Ligand Interactions during Plasmodium falciparum Invasion of Erythrocytes. *PLoS Pathog*. 2015; 11(2): e1004670. doi: [10.1371/journal.ppat.1004670](#) PMID: [25723550](#).
11. Besteiro S, Michelin A, Poncet J, Dubremetz JF, Lebrun M. Export of a *Toxoplasma gondii* rhoptry neck protein complex at the host cell membrane to form the moving junction during invasion. *PLoS Pathog*. 2009; 5(2): e1000309. doi: [10.1371/journal.ppat.1000309](#) PMID: [19247437](#).
12. Lamarque M, Besteiro S, Papoin J, Roques M, Vulliez-Le Normand B, Morlon-Guyot J, et al. The RON2-AMA1 interaction is a critical step in moving junction-dependent invasion by apicomplexan parasites. *PLoS Pathog*. 2011; 7(2): e1001276. doi: [10.1371/journal.ppat.1001276](#) PMID: [21347343](#).
13. Fritz HM, Bowyer PW, Bogyo M, Conrad PA, Boothroyd JC. Proteomic analysis of fractionated *Toxoplasma* oocysts reveals clues to their environmental resistance. *PLoS One*. 2012; 7(1): e29955. doi: [10.1371/journal.pone.0029955](#) PMID: [22279555](#).
14. Lamarque MH, Roques M, Kong-Hap M, Tonkin ML, Rugarabamu G, Marq JB, et al. Plasticity and redundancy among AMA-RON pairs ensure host cell entry of *Toxoplasma* parasites. *Nat Commun*. 2014; 5: 4098. doi: [10.1038/ncomms5098](#) PMID: [24934579](#).

15. Poukchanski A, Fritz HM, Tonkin ML, Treeck M, Boulanger MJ, Boothroyd JC. *Toxoplasma gondii* sporozoites invade host cells using two novel paralogues of RON2 and AMA1. *PLoS One*. 2013; 8(8): e70637. doi: [10.1371/journal.pone.0070637](https://doi.org/10.1371/journal.pone.0070637) PMID: [23940612](https://pubmed.ncbi.nlm.nih.gov/23940612/).
16. Gajria B, Bahl A, Brestelli J, Dommer J, Fischer S, Gao X, et al. ToxoDB: an integrated *Toxoplasma gondii* database resource. *Nucleic Acids Res*. 2008; 36(Database issue): D553–556. doi: [10.1093/nar/gkm981](https://doi.org/10.1093/nar/gkm981) PMID: [18003657](https://pubmed.ncbi.nlm.nih.gov/18003657/).
17. Tonkin ML, Crawford J, Lebrun ML, Boulanger MJ. *Babesia divergens* and *Neospora caninum* apical membrane antigen 1 structures reveal selectivity and plasticity in apicomplexan parasite host cell invasion. *Protein Sci*. 2013; 22(1): 114–127. doi: [10.1002/pro.2193](https://doi.org/10.1002/pro.2193) PMID: [23169033](https://pubmed.ncbi.nlm.nih.gov/23169033/).
18. Tonkin ML, Roques M, Lamarque MH, Pugnieri M, Douguet D, Crawford J, et al. Host cell invasion by apicomplexan parasites: insights from the co-structure of AMA1 with a RON2 peptide. *Science*. 2011; 333(6041): 463–467. doi: [10.1126/science.1204988](https://doi.org/10.1126/science.1204988) PMID: [21778402](https://pubmed.ncbi.nlm.nih.gov/21778402/).
19. Vulliez-Le Normand B, Tonkin ML, Lamarque MH, Langer S, Hoos S, Roques M, et al. Structural and functional insights into the malaria parasite moving junction complex. *PLoS Pathog*. 2012; 8(6): e1002755. doi: [10.1371/journal.ppat.1002755](https://doi.org/10.1371/journal.ppat.1002755) PMID: [22737069](https://pubmed.ncbi.nlm.nih.gov/22737069/).
20. Coley AM, Gupta A, Murphy VJ, Bai T, Kim H, Foley M, et al. Structure of the malaria antigen AMA1 in complex with a growth-inhibitory antibody. *PLoS Pathog*. 2007; 3(9): 1308–1319. doi: [10.1371/journal.ppat.0030138](https://doi.org/10.1371/journal.ppat.0030138) PMID: [17907804](https://pubmed.ncbi.nlm.nih.gov/17907804/).
21. Collins CR, Withers-Martinez C, Hackett F, Blackman MJ. An inhibitory antibody blocks interactions between components of the malarial invasion machinery. *PLoS Pathog*. 2009; 5(1): e1000273. doi: [10.1371/journal.ppat.1000273](https://doi.org/10.1371/journal.ppat.1000273) PMID: [19165323](https://pubmed.ncbi.nlm.nih.gov/19165323/).
22. Bargieri D, Lagal V, Andenmatten N, Tardieux I, Meissner M, Menard R. Host cell invasion by apicomplexan parasites: the junction conundrum. *PLoS Pathog*. 2014; 10(9): e1004273. doi: [10.1371/journal.ppat.1004273](https://doi.org/10.1371/journal.ppat.1004273) PMID: [25232721](https://pubmed.ncbi.nlm.nih.gov/25232721/).
23. Bai T, Becker M, Gupta A, Strike P, Murphy VJ, Anders RF, et al. Structure of AMA1 from *Plasmodium falciparum* reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. *Proc Natl Acad Sci U S A*. 2005; 102(36): 12736–12741. doi: [10.1073/pnas.0501808102](https://doi.org/10.1073/pnas.0501808102) PMID: [16129835](https://pubmed.ncbi.nlm.nih.gov/16129835/).
24. Crawford J, Tonkin ML, Grujic O, Boulanger MJ. Structural characterization of apical membrane antigen 1 (AMA1) from *Toxoplasma gondii*. *J Biol Chem*. 2010; 285(20): 15644–15652. doi: [10.1074/jbc.M109.092619](https://doi.org/10.1074/jbc.M109.092619) PMID: [20304917](https://pubmed.ncbi.nlm.nih.gov/20304917/).
25. Pizarro JC, Vulliez-Le Normand B, Chesne-Seck ML, Collins CR, Withers-Martinez C, Hackett F, et al. Crystal structure of the malaria vaccine candidate apical membrane antigen 1. *Science*. 2005; 308(5720): 408–411. doi: [10.1126/science.1107449](https://doi.org/10.1126/science.1107449) PMID: [15731407](https://pubmed.ncbi.nlm.nih.gov/15731407/).
26. Lim SS, Yang W, Krishnarajana B, Kannan Sivaraman K, Chandrashekar IR, Kass I, et al. Structure and dynamics of apical membrane antigen 1 from *Plasmodium falciparum* FVO. *Biochemistry*. 2014; 53(46): 7310–7320. doi: [10.1021/bi5012089](https://doi.org/10.1021/bi5012089) PMID: [25360546](https://pubmed.ncbi.nlm.nih.gov/25360546/).
27. Ge X, MacRaild CA, Devine SM, Debono CO, Wang G, Scammells PJ, et al. Ligand-induced conformational change of *Plasmodium falciparum* AMA1 detected using 19F NMR. *J Med Chem*. 2014; 57(15): 6419–6427. doi: [10.1021/jm500390g](https://doi.org/10.1021/jm500390g) PMID: [25068708](https://pubmed.ncbi.nlm.nih.gov/25068708/).
28. Leslie AGW. Recent changes to the MOSFLM package for processing film and image plate data. *Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography*. 1992; 26.
29. Evans P. Scaling and assessment of data quality. *Acta Crystallogr D Biol Crystallogr*. 2006; 62(Pt 1): 72–82. doi: [10.1107/S0907444905036693](https://doi.org/10.1107/S0907444905036693) PMID: [16369096](https://pubmed.ncbi.nlm.nih.gov/16369096/).
30. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, et al. Overview of the CCP4 suite and current developments. *Acta Crystallogr D Biol Crystallogr*. 2011; 67(Pt 4): 235–242. doi: [10.1107/S0907444910045749](https://doi.org/10.1107/S0907444910045749) PMID: [21460441](https://pubmed.ncbi.nlm.nih.gov/21460441/).
31. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. *J Appl Crystallogr*. 2007; 40(Pt 4): 658–674. doi: [10.1107/S0021889807021206](https://doi.org/10.1107/S0021889807021206) PMID: [19461840](https://pubmed.ncbi.nlm.nih.gov/19461840/).
32. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr*. 2004; 60(Pt 12): 2126–2132. doi: [10.1107/S0907444904019158](https://doi.org/10.1107/S0907444904019158) PMID: [15572765](https://pubmed.ncbi.nlm.nih.gov/15572765/).
33. Afonine PV, Grosse-Kunstleve RW, Echols N, Headd JJ, Moriarty NW, Mustyakimov M, et al. Towards automated crystallographic structure refinement with phenix.refine. *Acta Crystallogr D Biol Crystallogr*. 2012; 68(Pt 4): 352–367. doi: [10.1107/S0907444912001308](https://doi.org/10.1107/S0907444912001308) PMID: [22505256](https://pubmed.ncbi.nlm.nih.gov/22505256/).
34. Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, et al. MolProbity: all-atom structure validation for macromolecular crystallography. *Acta Crystallogr D Biol Crystallogr*. 2010; 66(Pt 1): 12–21. doi: [10.1107/S0907444909042073](https://doi.org/10.1107/S0907444909042073) PMID: [20057044](https://pubmed.ncbi.nlm.nih.gov/20057044/).
35. Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. *J Mol Biol*. 2007; 372(3): 774–797. doi: [10.1016/j.jmb.2007.05.022](https://doi.org/10.1016/j.jmb.2007.05.022) PMID: [17681537](https://pubmed.ncbi.nlm.nih.gov/17681537/).

36. Tonkin ML, Boulanger MJ. The shear stress of host cell invasion: exploring the role of biomolecular complexes. *PLoS Pathog.* 2015; 11(1): e1004539. doi: [10.1371/journal.ppat.1004539](https://doi.org/10.1371/journal.ppat.1004539) PMID: [25629317](https://pubmed.ncbi.nlm.nih.gov/25629317/).
37. Miller LH, Ackerman HC, Su XZ, Wellems TE. Malaria biology and disease pathogenesis: insights for new treatments. *Nat Med.* 2013; 19(2): 156–167. doi: [10.1038/nm.3073](https://doi.org/10.1038/nm.3073) PMID: [23389616](https://pubmed.ncbi.nlm.nih.gov/23389616/).
38. Kortagere S. Screening for small molecule inhibitors of *Toxoplasma gondii*. Expert opinion on drug discovery. 2012; 7(12): 1193–1206. doi: [10.1517/17460441.2012.729036](https://doi.org/10.1517/17460441.2012.729036) PMID: [22998671](https://pubmed.ncbi.nlm.nih.gov/22998671/).
39. Srinivasan P, Ekanem E, Diouf A, Tonkin ML, Miura K, Boulanger MJ, et al. Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria. *Proc Natl Acad Sci U S A.* 2014; 111(28): 10311–10316. doi: [10.1073/pnas.1409928111](https://doi.org/10.1073/pnas.1409928111) PMID: [24958881](https://pubmed.ncbi.nlm.nih.gov/24958881/).
40. Paul AS, Egan ES, Duraisingh MT. Host-parasite interactions that guide red blood cell invasion by malaria parasites. *Current opinion in hematology.* 2015; 22(3): 220–226. doi: [10.1097/MOH.000000000000135](https://doi.org/10.1097/MOH.000000000000135) PMID: [25767956](https://pubmed.ncbi.nlm.nih.gov/25767956/).
41. Macraill CA, Anders RF, Foley M, Norton RS. Apical membrane antigen 1 as an anti-malarial drug target. *Current topics in medicinal chemistry.* 2011; 11(16): 2039–2047. PMID: [21619512](https://pubmed.ncbi.nlm.nih.gov/21619512/).
42. Alam A. Bioinformatic Identification of Peptidomimetic-Based Inhibitors against *Plasmodium falciparum* Antigen AMA1. *Malaria research and treatment.* 2014; 2014: 642391. doi: [10.1155/2014/642391](https://doi.org/10.1155/2014/642391) PMID: [25580351](https://pubmed.ncbi.nlm.nih.gov/25580351/).
43. Srinivasan P, Yasgar A, Luci DK, Beatty WL, Hu X, Andersen J, et al. Disrupting malaria parasite AMA1-RON2 interaction with a small molecule prevents erythrocyte invasion. *Nat Commun.* 2013; 4: 2261. doi: [10.1038/ncomms3261](https://doi.org/10.1038/ncomms3261) PMID: [23907321](https://pubmed.ncbi.nlm.nih.gov/23907321/).
44. Lim SS, Debono CO, MacRaild CA, Chandrashekar IR, Dolezal O, Anders RF, et al. Development of Inhibitors of *Plasmodium falciparum* Apical Membrane Antigen 1 Based on Fragment Screening. *Aust J Chem.* 2013; 66(12): 1530–1536. doi: [10.1071/Ch13266](https://doi.org/10.1071/Ch13266) PMID: [WOS:000328001000010](https://pubmed.ncbi.nlm.nih.gov/WOS:000328001000010/).
45. Wang G, MacRaild CA, Mohanty B, Mobli M, Cowieson NP, Anders RF, et al. Molecular insights into the interaction between *Plasmodium falciparum* apical membrane antigen 1 and an invasion-inhibitory peptide. *PLoS One.* 2014; 9(10): e109674. doi: [10.1371/journal.pone.0109674](https://doi.org/10.1371/journal.pone.0109674) PMID: [25343578](https://pubmed.ncbi.nlm.nih.gov/25343578/).
46. Urquiza M, Suarez JE, Cardenas C, Lopez R, Puentes A, Chavez F, et al. *Plasmodium falciparum* AMA-1 erythrocyte binding peptides implicate AMA-1 as erythrocyte binding protein. *Vaccine.* 2000; 19(4–5): 508–513. PMID: [11027815](https://pubmed.ncbi.nlm.nih.gov/11027815/).
47. Fraser TS, Kappe SH, Narum DL, VanBuskirk KM, Adams JH. Erythrocyte-binding activity of *Plasmodium yoelii* apical membrane antigen-1 expressed on the surface of transfected COS-7 cells. *Mol Biochem Parasitol.* 2001; 117(1): 49–59. PMID: [11551631](https://pubmed.ncbi.nlm.nih.gov/11551631/).
48. Kato K, Mayer DC, Singh S, Reid M, Miller LH. Domain III of *Plasmodium falciparum* apical membrane antigen 1 binds to the erythrocyte membrane protein Kx. *Proc Natl Acad Sci U S A.* 2005; 102(15): 5552–5557. doi: [10.1073/pnas.0501594102](https://doi.org/10.1073/pnas.0501594102) PMID: [15805191](https://pubmed.ncbi.nlm.nih.gov/15805191/).
49. Valbuena J, Rodriguez L, Vera R, Puentes A, Curtidor H, Cortes J, et al. Synthetic peptides from *Plasmodium falciparum* apical membrane antigen 1 (AMA-1) specifically interacting with human hepatocytes. *Biochimie.* 2006; 88(10): 1447–1455. doi: [10.1016/j.biochi.2006.05.005](https://doi.org/10.1016/j.biochi.2006.05.005) PMID: [16765504](https://pubmed.ncbi.nlm.nih.gov/16765504/).
50. Montero E, Rodriguez M, Oksov Y, Lobo CA. *Babesia divergens* apical membrane antigen 1 and its interaction with the human red blood cell. *Infect Immun.* 2009; 77(11): 4783–4793. doi: [10.1128/IAI.00969-08](https://doi.org/10.1128/IAI.00969-08) PMID: [19720759](https://pubmed.ncbi.nlm.nih.gov/19720759/).
51. Bargieri DY, Andenmatten N, Lagal V, Thiberge S, Whitelaw JA, Tardieux I, et al. Apical membrane antigen 1 mediates apicomplexan parasite attachment but is dispensable for host cell invasion. *Nat Commun.* 2013; 4: 2552. doi: [10.1038/ncomms3552](https://doi.org/10.1038/ncomms3552) PMID: [24108241](https://pubmed.ncbi.nlm.nih.gov/24108241/).